A Study of Cognitive Health in Survivors of Prostate Cancer

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 8, 2026 → Sep 8, 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 8, 2026 to Sep 8, 2027
    • Eligibility criteria shortened, about 19 words
  2. Primary and study completion dates: Sep 8, 2025 to Sep 8, 2026v8
  3. Re-verified, no change to tracked fieldsv7
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 7 of 7 sites
    v6
  5. Primary and study completion dates: Sep 8, 2024 to Sep 8, 2025v5
Show 3 earlier versionsHide 3 earlier versions
  1. 2 versions Re-verified since Jan 20, 2023, no change to tracked fieldsv3-v4
  2. Eligibility criteria shortened, about 5 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to collect information that may help the researchers understand the relationship between prostate cancer survivors' experiences of cancer-related cognitive dysfunction (CRCD) and their other conditions (co-morbid factors), including anxiety, depression, and insomnia. The researchers will also find out how additional things may contribute to CRCD, including social factors, the characteristics of participants' prostate cancer, and the type of cancer treatment or other medications they received.
Trial Details
NCT Number NCT05540782
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Prostate Cancer, Survivorship
Related terms Prostatic Neoplasms
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov